Probmet Therapeutics has developed a peptide mimetic against the neuropeptide LGI1 to target the receptor ADAM22 as a targeted therapeutic and biomarker selection strategy to treat breast cancer brain metastasis.
Target Identification & Validation
ADAM22 is a unique cancer-specific target that was identified in a longitudinal clinical trial of matched primary and metastatic tumours from breast cancer patients.
ADAM22 as a target has been validated in human and animal models of breast cancer. Over 70% of primary breast tumours and over 90% of metastatic tumours express druggable levels of ADAM22.
Drug development and validation
A peptide drug targeting ADAM22 was developed in silico and demonstrated very strong efficacy at reducing tumour cell growth in human and animal models of breast cancer. Meet the team
Crucially, the peptide easily crosses the blood-brain barrier allowing for effective treatment of breast cancer brain metastases.